폐암 환자와 폐암 세포주를 주입한 Nude Mice에서 종양성장인자의 변화 = Changes in Tumor Growth Factors from Lung Cancer Patient and Nude Mice Injected with Lung Cancer Cell Lines
Background and purpose : The incidence of non-small cell lung cancer has decreased than past decades but the prevalence rate of squamous cell carcinoma is highest among the various types of lung cancer. There have been one of the most difficult problems of the medical areas because of the law rate of operative treatment by micrometastasis still. The released growth regulating factors from the tumor cells have heen researching targets recently. This study is to know the changes of the tumor growth factors by examining the change of transforming growth factor-β1 (TGF-β1) within plasma of nude mouse was measured after each of different quantity of cultured cell of squamous cell carcinoma was injected into plerual caviry of nude mouse in animal experiment, while comparing the values of TGF, Insulin-like growth factor and epidermal growth factor between experimental trial and clinical trial.
Method : Between June of 2006 and June of 2007 at Kosin University Hospital, 17 patients were chosen for this study where 13 of them were pathologically diagnosed of squamous cell carcinoma after initial diagnosis of lung cancer followed by radical pneumonectomy and pathologic biopsy, while 4 patients were pathologically diagnosed of benign tumor. Blood sample was collected prior to a surgery from the lung cancer patients scheduled for surgery, and the sample was cryopreserved. During surgery, dense tumor tissue without necrosis was excised in a size of 5mm3 and quickly frozen to be used for experimental tissue, whereas the tissue, which was located farthest from the lesion and deemed free of cancer cell, was to be used for control tissue. And the tissue obtained from benign tumor or normal tissue of granuloma patient was classified as a control tissue B, while the sample from malignant tissue of lung cancer was categorized as experimental tissue M. In animal experiment with 15 male nude mice without immunity, 5 subjects without cancer cell were used for control group, another 5 subjects with of 2×106 of cancer cell line (SW-900 G IV) injected into intrathoracic were used for experimental group I, and the other 5 subjects injected with twice quantity of cancer cell line of group I were classified as experimental group II. After breeding the subjects in the clean room for 8 weeks, blood sample was collected from their heart, and quantitative test of plasma TGF-β was performed. For the test of tumor growth factor, human TGF-β ELISA kit was used for quantitation of TGF-β1&2, and active TM non-eztraction IGF kit was for quantitation of IGF-I&II, while GE healthcare kit was used for EGF.
Results : In animal experiment, TGF-β1 was expressed within the serum of all nude mice from control group as well experimental group I and II, where control group was at 28.49 fmol/ml while experimental group I and II were at 32.19 fmol/ml and 42.36 fmol/ml respectively. In clinical trial, TGF-β1 was measured higher from experimental group with 40.9 fmol/ml than from control group with 28.5 fmol/ml, and TGF-β2 was lower from experimental group with 12.3 fmol/ml than from control group with 30.3 fmol/ml, while the difference was insignificant with EGF (p<0.05) where control group and experimental group were at 0.11 ng.ml and 0.12 ng/ml respectively. Moreover, TGF-β1 was at 40.88 fmol/ml from control tissue B and at 15.55 fmol/ml from experimental tissue M, where as TGF-β2 was at 12.31 fmol/ml from control tissue B and 23.95 fmol/ml from experimental tissue M (p<0.05). TGF-β1 within the serum of control group was at 812.4 fmol/ml before surgery and at 989.1 fmol/ml after surgery, which showed a slight amplifiction, while TGF-β2 was at 16.8 fmol/ml before surgery and at 20.2 fmol/ml after surgery, exhibiting a slight increase (p<0.05). Serum IGF-I was at 117.9 ng/ml before surgery and at 214.4 ng/ml after surgery, and IGF-II was at 552.8 ng/ml and 552.8 ng/ml after surgery, while EGF showed insignificant changes between before surgery at 0.67 ng/ml and after surgery at 0.74 ng/ml (p<0.05). In lung cancer stage Ia,b, TGF-β1 was decreased through surgery as it was at 972.94 mol/ml before and 866.92 mol/ml after, and TGF-β2 was also decreased as measured at 42.40 mol/ml before surgery and 38.24 mol/ml after surgery. In stage IIIa,b, TGF-β1 was decreased as measured at 980.31 mol/ml before surgery and at 928.18 mol/ml, while TGF-β2 showed not much changes (p<0.05). In lung cancer stage Ia,b, serum IGF-I was decreased as measured at 112.7 mol/ml before surgery and at 87.92 mol/ml after surgery. and IGF-II was also decreased as measured 468.78 ng/ml before surgery and at 358.59 ng/ml after surgery (p<0.05). In stage III,b, IGF-I showed not much changes, but IGF-II was at 438.31 ng/ml before surgery and 404.2 ng/ml after surgery, where EGF was not all influenced by the phase.
Conclusion : In the experiment with nude mice, TGF-β1 was increased as the number of cancer cell was increased after injection of cancer cell. The number of cancer cell from early tumor, such as Ia,b from post-surgery clinical lung cancer patients, was reduced after the surgery, and TGF-β1 was also reduced as the cancer cell was reduced as well. Therefore, it was believed that TGF-β1 can be a feasible prognostic factor for early diagnosis of lung cancer at Ia,b of early phase
분석정보
연월일 | 이력구분 | 이력상세 | 등재구분 |
---|---|---|---|
2027 | 평가예정 | 재인증평가 신청대상 (재인증) | |
2021-01-01 | 평가 | 등재학술지 유지 (재인증) | KCI등재 |
2018-01-01 | 평가 | 등재학술지 선정 (계속평가) | KCI등재 |
2017-01-01 | 평가 | 등재후보학술지 유지 (계속평가) | KCI후보 |
2015-01-01 | 평가 | 등재후보학술지 선정 (신규평가) | KCI후보 |
기준연도 | WOS-KCI 통합IF(2년) | KCIF(2년) | KCIF(3년) |
---|---|---|---|
2016 | 0.02 | 0.02 | 0.03 |
KCIF(4년) | KCIF(5년) | 중심성지수(3년) | 즉시성지수 |
0.04 | 0.04 | 0.21 | 0 |
서지정보 내보내기(Export)
닫기소장기관 정보
닫기권호소장정보
닫기오류접수
닫기오류 접수 확인
닫기음성서비스 신청
닫기음성서비스 신청 확인
닫기이용약관
닫기학술연구정보서비스 이용약관 (2017년 1월 1일 ~ 현재 적용)
학술연구정보서비스(이하 RISS)는 정보주체의 자유와 권리 보호를 위해 「개인정보 보호법」 및 관계 법령이 정한 바를 준수하여, 적법하게 개인정보를 처리하고 안전하게 관리하고 있습니다. 이에 「개인정보 보호법」 제30조에 따라 정보주체에게 개인정보 처리에 관한 절차 및 기준을 안내하고, 이와 관련한 고충을 신속하고 원활하게 처리할 수 있도록 하기 위하여 다음과 같이 개인정보 처리방침을 수립·공개합니다.
주요 개인정보 처리 표시(라벨링)
목 차
3년
또는 회원탈퇴시까지5년
(「전자상거래 등에서의 소비자보호에 관한3년
(「전자상거래 등에서의 소비자보호에 관한2년
이상(개인정보보호위원회 : 개인정보의 안전성 확보조치 기준)개인정보파일의 명칭 | 운영근거 / 처리목적 | 개인정보파일에 기록되는 개인정보의 항목 | 보유기간 | |
---|---|---|---|---|
학술연구정보서비스 이용자 가입정보 파일 | 한국교육학술정보원법 | 필수 | ID, 비밀번호, 성명, 생년월일, 신분(직업구분), 이메일, 소속분야, 웹진메일 수신동의 여부 | 3년 또는 탈퇴시 |
선택 | 소속기관명, 소속도서관명, 학과/부서명, 학번/직원번호, 휴대전화, 주소 |
구분 | 담당자 | 연락처 |
---|---|---|
KERIS 개인정보 보호책임자 | 정보보호본부 김태우 | - 이메일 : lsy@keris.or.kr - 전화번호 : 053-714-0439 - 팩스번호 : 053-714-0195 |
KERIS 개인정보 보호담당자 | 개인정보보호부 이상엽 | |
RISS 개인정보 보호책임자 | 대학학술본부 장금연 | - 이메일 : giltizen@keris.or.kr - 전화번호 : 053-714-0149 - 팩스번호 : 053-714-0194 |
RISS 개인정보 보호담당자 | 학술진흥부 길원진 |
자동로그아웃 안내
닫기인증오류 안내
닫기귀하께서는 휴면계정 전환 후 1년동안 회원정보 수집 및 이용에 대한
재동의를 하지 않으신 관계로 개인정보가 삭제되었습니다.
(참조 : RISS 이용약관 및 개인정보처리방침)
신규회원으로 가입하여 이용 부탁 드리며, 추가 문의는 고객센터로 연락 바랍니다.
- 기존 아이디 재사용 불가
휴면계정 안내
RISS는 [표준개인정보 보호지침]에 따라 2년을 주기로 개인정보 수집·이용에 관하여 (재)동의를 받고 있으며, (재)동의를 하지 않을 경우, 휴면계정으로 전환됩니다.
(※ 휴면계정은 원문이용 및 복사/대출 서비스를 이용할 수 없습니다.)
휴면계정으로 전환된 후 1년간 회원정보 수집·이용에 대한 재동의를 하지 않을 경우, RISS에서 자동탈퇴 및 개인정보가 삭제처리 됩니다.
고객센터 1599-3122
ARS번호+1번(회원가입 및 정보수정)